Is lenvatinib a targeted drug or an immune drug? How effective is it?

Lenvatinib (also known as Lenvatinib, trade name Lenvima/Lenvima), as a high-profile anti-cancer drug, is developed and produced by Eisai Pharmaceuticals of Japan Eisai Pharmaceuticals. Its ownership and efficacy have always been the focus of attention of patients and doctors. So, is lenvatinib a targeted drug or an immune drug?

Lenvatinib is clearly classified as a targeted drug, not an immunological drug or a chemotherapy drug. Targeted cancer treatments work by precisely affecting specific target molecules that cause cancer to grow and spread, often referred to as "precision medicine." Lenvatinib is a multi-kinase target inhibitor that blocks cellular proteins and signals to blood vessels, thereby helping to inhibit the survival and spread of cancer.

The efficacy of lenvatinib has been demonstrated in multiple clinical trials. For example, in a study of differentiated thyroid cancer (DTC), patients treated with lenvatinib survived significantly longer without disease progression and had a much higher rate of tumor shrinkage than patients who received placebo. In addition, for unresectable hepatocellular carcinoma, based onREFLECT phase 3 study, lenvatinib and sorafenib have similar efficacy, but perform better in terms of median overall survival, progression-free survival and objective response rate.

In addition, lenvatinib is also used in combination with other drugs to treat advanced renal cell carcinoma and advanced endometrial cancer, and has achieved significant therapeutic effects. Especially in combination with pembrolizumab, lenvatinib has demonstrated a strong synergistic effect. In the CLEAR/KEYNOTE-581 trial for advanced renal cell carcinoma, the combination of lenvatinib and pembrolizumab showed significant improvements in progression-free survival, overall survival, and objective response rate compared with sunitinib alone. For the treatment of endometrial cancer, the median progression-free survival of the combination of lenvatinib and pembrolizumab is 6.6 months, which is better than that of the chemotherapy group. Compared with chemotherapy, combination therapy significantly reduced the risk of disease progression or death and improved the objective response rate, which was significantly improved compared with the chemotherapy group. This result further proves the important role of lenvatinib as a targeted drug in cancer treatment.

In summary, lenvatinib, as a targeted drug, works by precisely affecting specific target molecules in the growth and spread of cancer. Its remarkable efficacy demonstrated in multiple clinical trials provides new treatment options and hope for cancer patients. However, it is important to note that each patient's situation is unique, so your doctor's instructions and recommendations should be followed closely when using lenvatinib or any other drug.